Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort

BACKGROUND: Treatment options for patients with urothelial cancer (UC) refractory to platinum and immunotherapy are limited and survival is short. Enfortumab vedotin (EV) is a monoclonal anti-NECTIN4 antibody conjugated to monomethyl auristatin. It was recently approved because of superior survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Zschäbitz, Stefanie, Biernath, Nadine, Hilser, Thomas, Höllein, Alexander, Zengerling, Friedemann, Cascucelli, Jozefina, Paffenholz, Pia, Seidl, Daniel, Lutz, Christoph, Schlack, Katrin, Kingreen, Dorothea, Klümper, Niklas, Ivanyi, Philipp, von Amsberg, Gunhild, Heers, Hendrik, Roghmann, Florian, Tauber, Robert L., Cathomas, Richard, Hofer, Luisa, Niegisch, Günter, Klee, Melanie, Ehrenberg, Roland, Hassler, Andreas, Hadaschik, Boris A., Grünwald, Viktor, Darr, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Urothelial Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334227/
https://www.ncbi.nlm.nih.gov/pubmed/37441344
http://dx.doi.org/10.1016/j.euros.2023.04.018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334227/
https://www.ncbi.nlm.nih.gov/pubmed/37441344
http://dx.doi.org/10.1016/j.euros.2023.04.018

Ejemplares similares